Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Analysts at Trump ally Howard Lutnick’s former firm call RFK Jr. ‘an anti-vax, conspiracy theorist with inadequate training’

RFK Jr. was reportedly behind the ouster of FDA’s top vaccine official and said last week that around 10,000 employees will be laid off at the Department of Health and Human Services.

Fortune

Moderna and Novavax shares plunge after key FDA official steps down, citing discord with RFK Jr. who he says 'wishes subservient confirmation of his misinformation and lies'

Massive cuts to personnel and funding within the Department of Health and Human Services presents a headache for vaccine approval and development, analysts say.

Fortune

Trump administration at ‘war’ with mRNA technology: scientists alarmed vaccine skeptics could kill research

Public health experts are sounding the alarm over recent move by the NIH to collect information about funding for research into mRNA technology

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

Barchart

Are COVID-19 Vaccines Safe and Effective?

Five years after Donald Trump declared a national COVID-19 emergency, here's what the research says.

Reason

Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

MarketBeat

Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now?

A promising pipeline provides long-term potential for Moderna.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

MarketBeat

Do Wall Street Analysts Like Moderna Stock?

Moderna has continued to underperform the broader market over the past year and analysts remain cautious about the stock’s prospects.

Barchart

What has the UK Covid inquiry learned so far about vaccines and treatments?

In fourth part of the inquiry, questons were asked about vaccine trials, procurement and the UK’s preparedness for future pandemics

The Guardian - UK

Here's What to Expect From Moderna's Next Earnings Report

Moderna is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a significant triple-digit profit dip.

Barchart

As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.

Fortune

After a Reset Year, Is Moderna Stock Poised for a Comeback?

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

MarketBeat

Moderna Stock Plummets 16% After £819.59M Guidance Cut Over Respiratory Vaccine Flop

Moderna is expediting its cost-cutting program and rolling back R&D amid a drop in vaccination rates and low revenues from a new vaccine.

International Business Times UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Moderna surprises the Street by predicting a bigger-than-expected sales drop

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year

International Business Times

Moderna Stock Poised For Another Drop After Shaving Nearly $1 Billion Off Earnings Estimates

The drug maker's stock plunged more than 17% in pre-market trading after slashing its sales outlook.

Fortune

No norovirus vaccine exists—yet. Moderna says it’s ‘one step closer,’ and you may be eligible to participate in its ongoing clinical trial

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

Kiplinger

Stock Market Today: Stocks End Mixed After FOMC Minutes

The minutes from the December Fed meeting signaled central bankers' uncertainty over potential Trump administration policies.

Get all your
news in one place.

100’s of premium titles.
One news app.

Kiplinger

Moderna Stock Is Volatile Amid Bird Flu Developments

Moderna stock has been volatile this week as the first death in the U.S. connected to bird flu was reported. Here's what you need to know.

Barchart

What Were the 4 Worst-Performing Stocks in the S&P 500 in 2024?

As 2025 starts to unfold, let's take a look back at the four worst-performing stocks in the S&P 500 from last year.

MarketBeat

Moderna Shares Spike on H5N1 News—What’s Next for Investors?

MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025

Fortune

Pediatric RSV vaccine trial paused by Moderna amid safety concerns

Five infants required hospitalization, with one needing mechanical ventilation.

Barchart

Is Moderna Stock Underperforming the Dow?

Moderna has significantly underperformed the Dow over the past year, and analysts are cautious about the stock’s prospects.

The Guardian - AU

Moderna’s mRNA vaccines to be exempt from advisory committee scrutiny under $2bn Morrison-era deal

Exclusive: Critics say exemption ‘deeply concerning’ and risks creating separate assessment systems

AAP

New vaccine facility a shot in the arm for Australians

Up to 100 million mRNA jabs will be made at Moderna's new plant, with a promise Australia will always be at the top of the vaccine queue for locally-made jabs.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.